Etoposide leukemogenicity;ETOPOSIDE ET RISQUE LEUCEMOGENE

Journal de Pharmacie Clinique

Volumn 17, Issue 2, 1998, Pages 71-73

  Guenfoudi Roullaud, M P ^a   Menat, C ^a   Girard, F ^a   Ansieau Picot, V ^a   Stoeckel, C ^a  

^a Hôpitaux Universitaires de Strasbourg   (France)

Author keywords

Etoposide; Leukemogenic potential; Secondary leukemia; Therapy related acute leukemia

Indexed keywords

ETOPOSIDE;

ACUTE LEUKEMIA; ARTICLE; CANCER RISK; DRUG ACCUMULATION; HUMAN; LEUKEMOGENESIS; SECOND CANCER;

EID: 0031810859     PISSN: 02911981     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Bajorin DF, Motzer RJ, Rodriguez E, Murphy B, Bosl GJ. Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 1993; 85: 60-2.
2. Bokemeyer C, Schmoll HJ, Huczyk MA, Beyer J, Siegert W. Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer (letter). J Natl Cancer Inst 1995 ; 87 : 58-60.
3. Boshoff C, Begent RH, Olivier RH, et al. Secondary tumors following etoposide containing therapy for germ cell cancer. Ann Oncol 1995; 6: 35-40.
4. Chen CL, Fuscoe JC, Liu Q, Mahmoud H, Relling MV. Relationship between cytotoxicity and side-specific DNA recombination after in vitro exposure of leukemia cells to etoposide. J Natl Cancer Inst 1996; 88: 1840-7.
5. De Jong RS, Mulder NH, Dijksterhuis D. Review of current clinical experience with prolonged (oral) etoposide in cancer treatment. Anticancer Res 1995; 15: 2319-30.
6. Goto H, Shimazaki C, Tatsumi T, et al. Acute myelomonocytic leukemia after treatment with chronic oral etoposide : are MLL and LTG 9 genes targets for etoposide ? Int J Hematol 1994 ; 60. 145-9
7. Hainsworth JD, Greco FA. Etoposide : twenty years later. Ann Oncol 1995; 6: 325-41.
8. Haupt R, Fears TR, Rosso P, et al. Increased risk of secondary leukemia after single-agent treatment with etoposide for Langerhans' cell histiocytosis. Ped Hematol Oncol 1994 ; 11 : 499-507.
9. Horibe K, Matsushita T, Numata S, et al. Acute promyelocytic leukemia with t(15;17) abnormality after chemotherapy containing etoposide for Langerhans' cell histiocytosis. Cancer 1993 ; 72 : 3723-6.
10. Matsuzaki A, Inamitsu T, Watanabe T, et al. Acute promyelocytic leukemia in a patient treated with etoposide for Langerhans' cell histiocytosis [review]. Br J Hematol 1994; 86: 887-9.
11. Nichols CR, Breeden ES, Loehrer PJ, Williams SD, Einhorn LH. Secondary leukemia associated with a conventional dose of etoposide : review of serial germ cell tumors protocols. J Natl Cancer Inst 1993, 85: 36-40.
12. Ozbek N, Cetin M, Tuncer AM, Yetsin S. Secondary acute myeloblastic leukemia in a child with acute lymphoblastic leukemia treated with epipodophyllotoxins. Turkish J Ped 1995 ; 37 : 279-82.
13. Pedersen-Bjergaard J, Hansen SW, Larsen SO, Daugaard G, Philip P, Rortn M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin and bleomycin for germ-cell tumors, Lancet 1991 ; 338 : 359-63.
14. Retain MJ, Rowley JD. Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II : from the bedside to the target genes. Ann Oncol 1992 ; 3 : 107-11.
15. Roulston D, Anastasi J, Rudinsky R, et al. Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21) : a report of two cases (letter). Blood 1995; 86: 3613-4.
16. Segelov E, Raghavan D, Coates A, Kronenberg H. Acute leukaemia following chemotherapy including etoposide for testicular carcinoma (letter). Australian & New Zealand. J Med 1993; 23 : 718-9.